This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (31)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Degeneration  • Articles for Residents  • Alert me on articles by topic  Social Bookmarking   What's this?

Ronald Klein, MD, MPH; Barbara E. K. Klein, MD; Sandra C. Tomany, MS; Lorraine G. Danforth, BS; Karen J. Cruickshanks, PhD

Arch Ophthalmol. 2003;121:1151-1155.

Objective  To examine the association of hydroxymethyl glutaryl coenzyme A reductase inhibitors (statins) with the 5-year incidence of age-related maculopathy (ARM).

Design  Population-based cohort study. Participants included persons 48 to 91 years old examined March 1, 1993, through June 14, 1995, living in Beaver Dam, Wis (N = 3684), of whom 2780 participated in a follow-up 5 years later.

Methods  Standardized procedures were used for physical examinations, blood sample collection, and questionnaire administration. Age-related maculopathy was determined by grading images of the posterior pole using a standard protocol. Standard univariate and multivariate analyses were performed.

Main Outcome Measures  Incidence and progression of ARM was measured over the 5-year interval.

Results  While controlling for age and sex, statin use was not found to be associated with the 5-year incidence of early ARM (odds ratio [OR], 1.12; 95% confidence interval [CI], 0.47-2.67), progression of ARM (OR, 1.22; 95% CI, 0.54-2.76), or incidence of late ARM (OR, 0.41; 95% CI, 0.12-1.45).

Conclusions  These findings do not suggest an association between statin use and incident ARM over a 5-year period. Further investigation of these relationships in larger studies over a longer period is needed.

From the Departments of Ophthalmology and Visual Sciences (Drs R. Klein, B. E. K. Klein, and Cruickshanks and Mss Tomany and Danforth) and Population Health Sciences (Dr Cruickshanks), University of Wisconsin Medical School, Madison. The authors have no relevant financial interest in this article.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Statins for all: the new premed?
Brookes et al.
Br J Anaesth 2009;103:99-107.
ABSTRACT | FULL TEXT  

Subclinical Atherosclerotic Cardiovascular Disease and Early Age-Related Macular Degeneration in a Multiracial Cohort: The Multiethnic Study of Atherosclerosis
Klein et al.
Arch Ophthalmol 2007;125:534-543.
ABSTRACT | FULL TEXT  

Statin Use and Incident Nuclear Cataract
Klein et al.
JAMA 2006;295:2752-2758.
ABSTRACT | FULL TEXT  

Dose-dependent effect of pitavastatin on VEGF and angiogenesis in a mouse model of choroidal neovascularization.
Zambarakji et al.
IOVS 2006;47:2623-2631.
ABSTRACT | FULL TEXT  

A 76-year-old man with macular degeneration.
Arroyo
JAMA 2006;295:2394-2406.
FULL TEXT  

3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Presence of Age-Related Macular Degeneration in the Cardiovascular Health Study
McGwin et al.
Arch Ophthalmol 2006;124:33-37.
ABSTRACT | FULL TEXT  

Mouse models may provide new insight into the relation between cholesterol and age related macular degeneration
Duncan
Br J Ophthalmol 2005;89:1549-1551.
FULL TEXT  

The relation between C reactive protein and age related macular degeneration in the Cardiovascular Health Study
McGwin et al.
Br J Ophthalmol 2005;89:1166-1170.
ABSTRACT | FULL TEXT  

A case control study of age related macular degeneration and use of statins
Smeeth et al.
Br J Ophthalmol 2005;89:1171-1175.
ABSTRACT | FULL TEXT  

Update of the vascular model of AMD
Friedman
Br J Ophthalmol 2004;88:161-163.
FULL TEXT